Protara Therapeutics Q1 2026 Earnings NarrowerthanExpected Loss Highlights Progress in Clinical Pipeline Annovis Bio Q1 2026 Earnings EPS Misses Estimates as PreClinical Spending Intensifies Alto Ingredients ALTO Q1 2026 Earnings Strong Profit Surprise Drives Share Rally CELH Q1 2026 Earnings Strong EPS Beat Drives Positive Stock Reaction NMTC Q1 2026 Earnings EPS Misses Estimates Stock Declines as Company Continues Development Phase iBio Q1 2026 Earnings EPS Miss Amid PreRevenue Stage Stock Rises 33